Emergent Biosolutions
EBS

$13.97

1.59%

Market Cap: 732M

About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Employees: 1,600

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 7 analysts

0

News positive %

of 8 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

112% more call options, than puts

Call options by funds: $1.12M | Put options by funds: $528K

7% less capital invested

Capital invested by funds: $98.2M [Q4 2023] → $91.1M (-$7.07M) [Q1 2024]

10.04% less ownership

Funds ownership: 78.84% [Q4 2023] → 68.8% (-10.04%) [Q1 2024]

11% less funds holding

Funds holding: 133 [Q4 2023] → 119 (-14) [Q1 2024]

37% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 46

41% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 34

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$5

64%

downside

Avg. target

$7.14

49%

downside

High target

$8

43%

downside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Benchmark Robert Wasserman	43%downside $8	Buy Reiterated	3 Jul 2024
Benchmark Robert Wasserman	43%downside $8	Buy Reiterated	2 Jul 2024
Benchmark Robert Wasserman	43%downside $8	Buy Reiterated	24 Jun 2024
Benchmark Robert Wasserman	43%downside $8	Buy Reiterated	21 Jun 2024
Benchmark Robert Wasserman	43%downside $8	Buy Maintained	20 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about EBS published over the past 30 days

Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay' Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith

GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the launch of a new opioid emergency awareness public education campaign to prepare people across the country to help save a life with the ‘Lay, Spray, Stay' method. Sponsored by Emergent and created in partnership with SAFE Project, a national nonprofit combating substance use, overdoses and addiction, the campaign stars Pro Football Hall of Famer, Emmitt Smith, in a series of public awareness video and radio segments. The effort supports Emergent's national Ready to Rescue initiative, which breaks down the stigma associated with accidental opioid poisonings and informs Americans on the availability and use of NARCAN® Nasal Spray to help save a life.

Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay' Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith

Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024

GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of 2024, as well as full year guidance.

Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024

Watch These 4 Overbought Stocks As Market Rotation Continues

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Watch These 4 Overbought Stocks As Market Rotation Continues

Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan

GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving its financial health, marked by robust cash generation and meaningful debt repayment. As set forth in its operational plan to transform the company over the next several years, Emergent is diligently executing its strategy to enhance operational efficiency, streamline costs, and generate cash to increase profitability and reduce the company's overall debt. This disciplined approach has enhanced Emergent's financial position, as well as enabling a customer focused, leaner and more flexible organization, and enriching its opportunities to pursue strategic initiatives.

Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan

Emergent, J&J settle COVID vaccine supply deal dispute

Emergent BioSolutions said on Monday Johnson & Johnson has agreed to pay $50 million to settle claims related to a terminated manufacturing deal for the latter's COVID-19 vaccine.

Emergent, J&J settle COVID vaccine supply deal dispute

Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?

Nvidia Corp NVDA is trading lower Tuesday amid reports that the company faces antitrust charges from French regulators.

Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?

Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism.

Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emergencies against anthrax, smallpox and botulism.

Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent's Contract Development and Manufacturing Organization (CDMO), has clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. Alongside the facility, approximately 350 current Emergent employees are expected to join Bora as part of the transaction.

Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million

Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day

GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- In recognition of National Naloxone Awareness Day, Emergent BioSolutions Inc. (NYSE: EBS) is highlighting its ongoing efforts to combat the opioid epidemic in the U.S., including topline results from its new general population awareness survey on consumers' understanding of opioid-related accidental overdose and fentanyl. The results show that there is a high level of awareness that fentanyl is an opioid, and that naloxone can reverse opioid overdoses, including those caused by fentanyl.1 It also found that there are still gaps in certain age groups and populations in understanding the role of naloxone in reversing opioid overdoses related to fentanyl.1

Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day

See News Rankings